Brainstorm Cell Therapeut...

NASDAQ: BCLI · Real-Time Price · USD
0.63
0.03 (5.00%)
At close: Aug 15, 2025, 2:51 PM

Brainstorm Cell Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
n/a n/a 343K 343K 343K 343K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost of Revenue
n/a 64K 130K 195K 195K 131K 135K 70K 70K 70K 70K 137K 137K 137K 67K n/a n/a
Gross Profit
n/a -633K -356K -421K -421K 212K -135K -70K -70K -70K -70K -137K -137K -137K -67K n/a n/a
Operating Income
-12.31M -11.69M -13.31M -16.3M -18.76M -21.44M -21.55M -22.36M -24.5M -24.82M -26.12M -24.55M -23.09M -24.54M -29.82M -29.03M -30.3M
Interest Income
76K 43K -49.12K -49.12K 40.88K 119.88K 212K 212K 92K 115K 137K 137K 137K 289K 267K 267K 267K
Pretax Income
-11.09M -11.62M -14.23M -12.75M -15.53M -17.19M -16.63M -22.26M -23.98M -24.28M -25.45M -23.93M -23.16M -24.46M -30.08M -29.23M -30.36M
Net Income
-11.09M -11.62M -14.23M -12.75M -15.53M -17.19M -16.63M -22.26M -23.98M -24.28M -25.45M -23.93M -23.16M -24.46M -30.08M -29.23M -30.36M
Selling & General & Admin
7.31M 7.04M 8.68M 9.38M 9.98M 10.69M 10.05M 10.41M 10.23M 10.87M 10.94M 9.53M 9.57M 9.3M 9.44M 10.4M 9.58M
Research & Development
4.94M 4.53M 4.56M 6.85M 8.72M 10.75M 11.5M 11.95M 14.26M 13.96M 15.18M 15.02M 13.51M 15.23M 20.38M 18.63M 20.72M
Other Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Operating Expenses
12.31M 11.63M 13.24M 16.23M 18.7M 21.44M 21.55M 22.36M 24.5M 24.82M 26.12M 24.55M 23.09M 24.54M 29.82M 29.03M 30.3M
Interest Expense
n/a n/a 92K 92K 92K 92K 103K 103K 103K 103K n/a 59K 59K 59K 383K 327K 327K
Selling & Marketing Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
12.31M 11.69M 13.31M 16.3M 18.76M 21.44M 21.55M 22.36M 24.5M 24.82M 26.12M 24.55M 23.09M 24.54M 29.82M 29.03M 30.3M
Income Tax Expense
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Shares Outstanding (Basic)
6.34M 5.71M 5.31M 4.75M 4.32M 3.36M 2.95M 2.65M 2.45M 2.44M 2.43M 2.43M 2.43M 2.42M 2.42M 2.42M 2.39M
Shares Outstanding (Diluted)
6.34M 5.71M 5.31M 4.75M 4.32M 3.36M 2.95M 2.65M 2.45M 2.44M 2.43M 2.43M 2.43M 2.42M 2.42M 2.42M 2.39M
EPS (Basic)
-2.06 -2.36 -1.91 -1.85 -3.26 -2.64 -2.67 -5.07 -5.97 -8.09 -8.12 -7.52 -7.22 -7.82 -7.98 -7.83 -9.03
EPS (Diluted)
-2.06 -2.36 -1.91 -1.85 -3.26 -4.61 -4.64 -7.04 -7.94 -8.09 -8.12 -7.52 -7.22 -7.82 -7.98 -7.83 -9.03
EBITDA
-12.08M -11.45M -13.83M -16.81M -19.27M -21.95M -21.28M -22.08M -24.22M -24.54M -25.83M -24.27M -22.81M -24.28M -29.56M -28.78M -30.07M
EBIT
-12.31M -11.69M -14.08M -17.07M -19.54M -22.21M -21.55M -22.36M -24.5M -24.82M -26.12M -24.55M -23.09M -24.54M -29.82M -29.03M -30.3M
Depreciation & Amortization
228K 240K 253K 259K 262K 265K 269K 274K 278K 285K 285K 282K 273K 260K 254K 243K 231K